Reach Us +44-3308187254


Testing The Two-hit Hypothesis Of Alzheimer Disease: Cell Cycle Re-entry | 13252
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Testing the two-hit hypothesis of Alzheimer disease: Cell cycle re-entry

International Summit on Clinical Pharmacy & Dispensing

George Perry

Keynote: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.001

The two-hit hypothesis of Alzheimer suggests cell cycle entry is a major factor in driving neuronal death in Alzheimer?s disease (AD). We experimentally addressed this issue by driving c-myc expression specifically in neurons with an inducible cam-kinase promoter. We confirmed that c-myc was specifically inducible in large cortical/hippocampal neurons. We found expression of c-myc led to histone phosphorylation, DNA fragmentation (TUNEL), gliosis, and neuronal death. The effects were specific to brain areas of increased expression and did not involve the cerebellum. Consistent with neuronal specificity, behavior analysis showed the deficits were cognitive rather than motor function. These findings support cell cycle re-entry as a critical hit of the two-hit hypothesis of AD and point to the attractiveness of intervention to modify neuronal cell cycle re-entry as a therapeutic target.
George Perry is Dean of the College of Sciences and Professor of Biology at The University of Texas at San Antonio, and Adjunct Professor of Pathology and Neurosciences at Case Western Reserve University. Perry is recognized in the field of Alzheimer?s disease research particularly for his work on oxidative metabolism. He is distinguished as one of the top Alzheimer?s disease researchers with over 1000 publications, and one of the top 100 most-cited scien tists in neuroscience and behavior. He is editor-in-chief for the Journal of Alzheimer's Disease, a Fellow of the American Association for the Advancement of Sciences, the Microscopy Society of America, the Royal Society of Chemistry, and past president of the American Association of Neuropathologists, as well as a member of the Dana Alliance for Brain Initiatives and a Fulbright Senior Specialist. Perry's research is primarily focused on how Alzheimer disease develops and the physiological consequences of the disease at a cellular level.